12 基因 Oncotype DX 结肠复发评分® 结果可量化 II/III 期结肠癌 (CC) 的复发风险。这项真实世界的研究调查了 II 期 CC 患者，他们的治疗决策纳入了复发评分® (RS) 结果。这项前瞻性设计队列的回顾性分析包括所有 II 期、错配修复熟练的 CC 患者，他们通过 Clalit 接受了 12 基因测试2011 年 1 月至 2016 年 12 月期间进行，并拥有至少 3 年随访的可用数据。该分析包括 938 名患者{中位年龄 68 [四分位距 (IQR) 60-76] 岁； 96% T3 肿瘤}。 RS 中位数为 26（IQR 19-33），三个 RS 类别（0-29、30-40、41-100）分别包括 65%、24% 和 11% 的患者。三个 RS 类别之间的化疗 (CT) 使用情况存在显着差异（分别为 14%、36% 和 60%；P < 0.001）。 CT 组和仅观察组不平衡，前者的临床病理特征较差。在仅观察的患者中，Kaplan-Meier (KM) 对无复发间隔 (RFI) 和 CC 特异性生存 (CCSS) 的估计在三个 RS 类别之间存在显着差异 (P < 0.001)。每个 RS 类别中的治疗临床结果（CT 与观察）显示，RS 0-29 和 30-40 类别中的 RFI 和 CCSS 没有差异。相比之下，在 RS 41-100 类别中，RFI 的差异趋于显着 (P = 0.066)，而对于 CCSS，观察到统计学上显着的差异，CT 治疗的患者预后更好 (P = 0.035)。结果是 II 期 CC 的预后。在 RS 41-100 患者中，尽管临床病理特征较差，但接受 CT 治疗的患者结局优于仅观察患者，这表明 CT 可为高危患者带来临床益处。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

The 12-gene Oncotype DX Colon Recurrence Score® result quantifies the recurrence risk in stage II/III colon cancer (CC). This real-world study investigated stage II CC patients whose treatment decisions incorporated the Recurrence Score® (RS) result.This retrospective analysis of a prospectively designed cohort included all stage II, mismatch repair-proficient CC patients who underwent 12-gene testing through Clalit between January 2011 and December 2016 and had available data with a minimum 3-year follow-up.The analysis included 938 patients {median age 68 [interquartile range (IQR) 60-76] years; 96% T3 tumors}. The median RS was 26 (IQR 19-33) and the three RS categories (0-29, 30-40, 41-100) included 65%, 24%, and 11% of patients, respectively. Chemotherapy (CT) use differed significantly between the three RS categories (14%, 36%, and 60%, respectively; P < 0.001). The CT and observation-only groups were imbalanced with worse clinicopathologic characteristics in the former. Among observation-only patients, Kaplan-Meier (KM) estimates for recurrence-free interval (RFI) and CC-specific survival (CCSS) differed significantly between the three RS categories (P < 0.001). Clinical outcomes by treatment (CT versus observation) within each RS category revealed no differences in RFI and CCSS in the RS 0-29 and 30-40 categories. In contrast, in the RS 41-100 category, the difference in RFI trended toward significance (P = 0.066), and for CCSS, a statistically significant difference was observed, with better outcomes among CT-treated patients (P = 0.035).RS results are prognostic in stage II CC. Among RS 41-100 patients, outcomes were better in CT-treated versus observation-only patients despite worse clinicopathologic characteristics, suggesting that CT confers clinical benefit in high-risk patients.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.